Texas A&M University Health Services Adopts FebriDx® in Student Medical Centers
24 December 2025
Lumos Diagnostics (ASX: LDX) is pleased to share that Texas A&M University Health Services has commenced the routine use of FebriDx® within its campus medical centers. Texas A&M is one of the largest university systems in the United States, with more than 80,000 students enrolled across multiple campuses.
Texas A&M’s University Health Services has been using FebriDx for several months, purchasing the test through Henry Schein, a sub-distributor of Lumos’ US commercial partner, PHASE Scientific. The university’s adoption represents an important step in Lumos’ expansion into the student health market, where acute respiratory infections are one of the leading reasons for clinical visits. Across the United States, one in two students will visit a student health clinic each year, and 70% consider campus health centres their primary source of care.
FebriDx is being used within Texas A&M University Health Services’ moderate-complexity campus medical centers. FebriDx supports their clinicians in distinguishing bacterial from non-bacterial acute respiratory infections at the point of care, improving clinical workflow and enhancing decision-making to help reduce unnecessary antibiotic use.
Doug Ward, Managing Director of Lumos Diagnostics said:
“Texas A&M University Health Services’ ongoing purchase orders provide a strong validation of FebriDx’s performance in a busy clinical environment and highlight the potential benefits of broader adoption across the student healthcare sector in the United States.”
Texas A&M’s University Health Services has been using FebriDx for several months, purchasing the test through Henry Schein, a sub-distributor of Lumos’ US commercial partner, PHASE Scientific. The university’s adoption represents an important step in Lumos’ expansion into the student health market, where acute respiratory infections are one of the leading reasons for clinical visits. Across the United States, one in two students will visit a student health clinic each year, and 70% consider campus health centres their primary source of care.
FebriDx is being used within Texas A&M University Health Services’ moderate-complexity campus medical centers. FebriDx supports their clinicians in distinguishing bacterial from non-bacterial acute respiratory infections at the point of care, improving clinical workflow and enhancing decision-making to help reduce unnecessary antibiotic use.
Doug Ward, Managing Director of Lumos Diagnostics said:
“Texas A&M University Health Services’ ongoing purchase orders provide a strong validation of FebriDx’s performance in a busy clinical environment and highlight the potential benefits of broader adoption across the student healthcare sector in the United States.”
